How PerkinElmer Beat Expectations in Q4

PerkinElmer (NYSE:PKI) stock skyrocketed 48% in 2020 — one of its best performances in years. The demand for COVID-19 testing was the primary factor behind that strong growth. Yet PerkinElmer hasn’t received a lot of attention from investors seeking to profit from the surge in testing.

The healthcare company announced its fourth-quarter results after the market close on Tuesday. Again, COVID-19 was the big story. Here are the highlights from PerkinElmer’s Q4 update. 

Gloved hands holding a coronavirus test vial and a cotton swab

Image source: Getty Images.

By the numbers

PerkinElmer reported revenue in the fourth quarter of $1.4 billion. This reflected a 68% increase from the prior-year period revenue total of $805 million. It also topped the Wall Street consensus estimate of $1.22 billion. 

How did PerkinElmer’s bottom line look in the fourth quarter? The company reported net income of $380.4 million, or $3.38 per share, based on generally accepted accounting principles (GAAP). This was a huge improvement from GAAP earnings of $64.5 million, or $0.58 per share, posted in the same period in 2019. 

The company’s adjusted net income in the fourth quarter came in at $3.96 per share — nearly triple the adjusted earnings of $1.35 recorded in the prior-year period. This result also trounced the average analyst adjusted earnings estimate of $3.00 per share.

READ:  Got $1,000 to Invest? Here's How to Turn It Into $45,000 With Zero Effort

Behind the numbers

PerkinElmer is organized into two business segments. There were striking differences between how those segments performed in the fourth quarter.

The company’s diagnostics segment ranked as its biggest moneymaker. The segment generated revenue of $852 million in the fourth quarter, jumping 176% year over year. This huge increase stemmed in large part from higher demand for COVID-19 testing.

Q4 revenue for PerkinElmer’s discovery and analytical solutions segment totaled $496 million, up only 1% year over year. On an organic basis, the segment’s revenue declined by 2% from the prior-year period.

The strong overall revenue growth boosted PerkinElmer’s earnings. It also helped that there was over $32 million in debt extinguishment costs incurred in the prior-year period compared to none in the fourth quarter of 2020.

Looking ahead

CEO Prahlad Singh said, “As we look ahead, I could not be more excited about the future for PerkinElmer.” That future looks pretty good, which could bode well for the healthcare stock in 2021.

PerkinElmer expects that revenue for full-year 2021 will be at least $4.08 billion. The company anticipates GAAP earnings per share (EPS) from continuing operations to be at least $6.73, with adjusted non-GAAP EPS of at least $8.50. 

READ:  U.S. Bancorp Q4 Earnings Meet Profit Expectations But Miss on Revenue

Probably the main wild card for the company will be how long demand remains strong for COVID-19 testing. However, with new coronavirus variants potentially extending the duration it will take for the world to reach herd immunity, it seems likely that PerkinElmer investors won’t have to be concerned about testing demand falling significantly anytime soon. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

View more information:

Xem thêm bài viết thuộc chuyên mục: investing

Related Articles

Leave a Reply

Back to top button